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ABSTRACT
TITLE: Nanotopography of substrates directs the deposition of fibrillar collagen by corneal stromal cells and
deposition is accelerated by macromolecular crowding
ABSTRACT BODY: 
Purpose: The corneal stroma consists of roughly orthogonal lamellae composed of collagen fibrils with
diameter of 25-30 nm. Traditional cell culture methods can take several months to create a thick construct
when trying to replicate the stroma in vitro. The aims of this study were to investigate the effects of using a
macromolecular crowder to accelerate collagen deposition by cells, with and without topographical cues, to
efficiently recapitulate the stroma in vitro. 
 
Methods: Aligned PTFE nanofibres were transferred onto glass coverslips using friction transfer. Cells isolated
from human corneo-scleral rims were seeded onto coverslips, aligned versus control, and cultured in either
complete media (NORM) or complete media with 75 μg/ml of carrageenan (CAR) for up to 30 days. A collagen
probe was added to culture media for 90 mins before constructs were fixed with 10% neutral buffered formalin
and imaged using confocal microscopy. The alignment of collagen fibres was analysed using OrientationJ, an
ImageJ plugin. In addition, immunocytochemistry (ICC) was performed to analyse the deposition of collagen
type I (Col I). For collagen fibre alignment, results reported are Welch’s t-test, SD and n=3. 
 
Results: Cells cultured in NORM deposited fibrillar collagen that aligned parallel to the topographical cues
provided by the aligned PTFE nanofibres. At 30 days, over 70% of collagen fibres deposited by the cells on the
PTFE nanofibres were aligned within ± 10°, compared to just 45% of the fibres deposited by cells on the
control (p<0.05). ICC revealed that from as early as day 7 there was an increase in deposition of collagen type
I by cells in CAR compared to NORM. When cells were cultured in CAR for a prolonged period of time, the
crowded collagen appeared to aggregate and fibre alignment was not promoted. ICC analysis of the
aggregates showed positive staining for Col I. 
 
Conclusions: OrientationJ analysis shows that the cells cultured on PTFE nanofibres in NORM deposit
parallel collagen fibres, emulating a lamella within the native corneal stroma. However, when cells are crowded
with CAR for 30 days, the collagen deposited appears aggregated, no longer forming fibres. This suggests that
whilst CAR may accelerate collagen deposition, further work is required to recapitulate the orthogonal
alignment of the collagen lamellae in the native corneal stroma. 
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